Literature DB >> 18350547

Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers.

T Scott Devera1, Hemangi B Shah, Gillian A Lang, Mark L Lang.   

Abstract

NKT cell activation with CD1d-binding glycolipid alpha-galactosylceramide (alpha-GC) enhances antibody responses to co-administered T-dependent antigen. The efficacy of alpha-GC relative to other CD1d-binding glycolipids and adjuvants is not known. There is little information on how NKT cells affect antibody production beyond initial booster-stimulated recall responses. We therefore tested the hypothesis that alpha-GC stimulates induction of plasma cells and antibody responses as effectively as Th1- and Th2-skewing variants of alpha-GC and several other adjuvants. C57BL/6 and CD1d-/- mice were immunized with nitrophenol-conjugated keyhole limpet hemocyanin (NP-KLH) plus alpha-GC or NP-KLH plus adjuvants before administration of an NP-KLH booster and assessing antibody responses and plasma cell frequency. alpha-GC boosted long-term antibody responses as efficiently as all other agents tested and induced plasma cells that were detected in bone marrow 13 weeks after immunization. We then determined whether NKT cells were required in the presence of other adjuvants. CD1d-/- mice had a reduced induction of plasma cells in response to NP-KLH/Alum as compared to C57BL/6 mice. However, NKT cells were not required for the continued presence of those cells that were induced. Although NKT cells are capable of inducing persistent plasma cell responses, they may not play a major role in supporting longevity post-induction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18350547      PMCID: PMC3500907          DOI: 10.1002/eji.200738000

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  44 in total

Review 1.  NKT cells: facts, functions and fallacies.

Authors:  D I Godfrey; K J Hammond; L D Poulton; M J Smyth; A G Baxter
Journal:  Immunol Today       Date:  2000-11

2.  A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

Authors:  Giuseppe Giaccone; Cornelis J A Punt; Yoshitaka Ando; Rita Ruijter; Nobusuke Nishi; Marlies Peters; B Mary E von Blomberg; Rik J Scheper; Hans J J van der Vliet; Alfons J M van den Eertwegh; Marja Roelvink; Jos Beijnen; Heinz Zwierzina; Herbert M Pinedo
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

3.  Strategies for selective priming of memory B cells.

Authors:  Vanitha S Raman; Evan F Lind; Micah J Benson; Randolph J Noelle
Journal:  Immunol Lett       Date:  2007-02-27       Impact factor: 3.685

4.  Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi.

Authors:  H Kumar; A Belperron; S W Barthold; L K Bockenstedt
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

5.  A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.

Authors:  K Miyamoto; S Miyake; T Yamamura
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

6.  Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice.

Authors:  Miho Mizuno; Makoto Masumura; Chiharu Tomi; Asako Chiba; Shinji Oki; Takashi Yamamura; Sachiko Miyake
Journal:  J Autoimmun       Date:  2004-12       Impact factor: 7.094

7.  Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway.

Authors:  Daniela O Procópio; Igor C Almeida; Ana Cláudia T Torrecilhas; Jarbas E Cardoso; Luc Teyton; Luiz R Travassos; Albert Bendelac; Ricardo T Gazzinelli
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

8.  Cutting edge: invariant V alpha 14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model.

Authors:  Mariette Lisbonne; Séverine Diem; Alexandre de Castro Keller; Jean Lefort; Luiza M Araujo; Patricia Hachem; Jean-Marie Fourneau; Stéphane Sidobre; Mitchell Kronenberg; Masuru Taniguchi; Peter Van Endert; Michel Dy; Philip Askenase; Momtchilo Russo; B Boris Vargaftig; André Herbelin; Maria C Leite-de-Moraes
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

9.  Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice.

Authors:  Tomohiro Yoshimoto; Booki Min; Takaaki Sugimoto; Nobuki Hayashi; Yuriko Ishikawa; Yuki Sasaki; Hitomi Hata; Kazuyoshi Takeda; Ko Okumura; Luc Van Kaer; William E Paul; Kenji Nakanishi
Journal:  J Exp Med       Date:  2003-04-14       Impact factor: 14.307

10.  CD1d-restricted help to B cells by human invariant natural killer T lymphocytes.

Authors:  Grazia Galli; Sandra Nuti; Simona Tavarini; Luisa Galli-Stampino; Claudia De Lalla; Giulia Casorati; Paolo Dellabona; Sergio Abrignani
Journal:  J Exp Med       Date:  2003-04-14       Impact factor: 14.307

View more
  34 in total

1.  Differential contribution of dendritic cell CD1d to NKT cell-enhanced humoral immunity and CD8+ T cell activation.

Authors:  Sunil K Joshi; Gillian A Lang; T Scott Devera; Amy M Johnson; Susan Kovats; Mark L Lang
Journal:  J Leukoc Biol       Date:  2012-02-13       Impact factor: 4.962

2.  CD40L-null NKT cells provide B cell help for specific antibody responses.

Authors:  Hemangi B Shah; Sunil K Joshi; Mark L Lang
Journal:  Vaccine       Date:  2011-09-28       Impact factor: 3.641

3.  Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides.

Authors:  Li Bai; Shenglou Deng; Rachel Reboulet; Rebecca Mathew; Luc Teyton; Paul B Savage; Albert Bendelac
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

Review 4.  Optimizing NKT cell ligands as vaccine adjuvants.

Authors:  Leandro J Carreño; Shalu Sharma Kharkwal; Steven A Porcelli
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

5.  Reduction of CD1d expression in vivo minimally affects NKT-enhanced antibody production but boosts B-cell memory.

Authors:  Gillian A Lang; Amy M Johnson; T Scott Devera; Sunil K Joshi; Mark L Lang
Journal:  Int Immunol       Date:  2011-03-12       Impact factor: 4.823

6.  Type II NKT cells facilitate Alum-sensing and humoral immunity.

Authors:  Hemangi B Shah; T Scott Devera; Pragya Rampuria; Gillian A Lang; Mark L Lang
Journal:  J Leukoc Biol       Date:  2012-07-13       Impact factor: 4.962

7.  Coordination between T helper cells, iNKT cells, and their follicular helper subsets in the humoral immune response against Clostridium difficile toxin B.

Authors:  Pragya Rampuria; Gillian A Lang; T Scott Devera; Casey Gilmore; Jimmy D Ballard; Mark L Lang
Journal:  J Leukoc Biol       Date:  2016-08-26       Impact factor: 4.962

Review 8.  Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants.

Authors:  Sungjune Kim; Saif Lalani; Vrajesh V Parekh; Lan Wu; Luc Van Kaer
Journal:  Expert Rev Vaccines       Date:  2008-12       Impact factor: 5.217

Review 9.  How do natural killer T cells help B cells?

Authors:  Mark L Lang
Journal:  Expert Rev Vaccines       Date:  2009-08       Impact factor: 5.217

10.  Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy.

Authors:  Sunil K Joshi; Gillian A Lang; Jason L Larabee; T Scott Devera; Lindsay M Aye; Hemangi B Shah; Jimmy D Ballard; Mark L Lang
Journal:  PLoS Pathog       Date:  2009-09-25       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.